This invention is directed to a biodegradable polymer that can be degraded in vivo. The biodegradable polymer comprises a biodegradable polymer segment having at least a biodegradable bond and two or more cationic components, wherein each of said cationic components is covalently attached to the bio
This invention is directed to a biodegradable polymer that can be degraded in vivo. The biodegradable polymer comprises a biodegradable polymer segment having at least a biodegradable bond and two or more cationic components, wherein each of said cationic components is covalently attached to the biodegradable polymer segment and the two cationic components/molecules are separated by at least one biodegradable bond in the backbone. The biodegradable polymer can be used for targeting desired ceils in vivo including T cells, NK (natural killer) ceils, cancer cells, or a combination thereof, delivering genes, DNA, oligodeoxynucleotide, oligonucleotide, RNA, mRNA, RNAi, siRNA, microRNA, protein, peptide, antibody, fragment of an antibody, small molecule drug including chemotherapy drugs, or other bioactive agents into cells, or being used as a vaccine or drug for treating a disease such as a cancer in a subject.
대표청구항▼
1.-26. (canceled) 27. A bioactive composition comprising a biodegradable polymer and at least one bioactive agent, wherein said biodegradable polymer comprises two or more cationic components and at least one biodegradable bond formed by biomolecules, wherein said two or more cationic components are
1.-26. (canceled) 27. A bioactive composition comprising a biodegradable polymer and at least one bioactive agent, wherein said biodegradable polymer comprises two or more cationic components and at least one biodegradable bond formed by biomolecules, wherein said two or more cationic components are separated by at least one of said at least one biodegradable bond, wherein said biodegradable polymer comprises at least one side chain; and wherein said two or more cationic components are attached to said biomolecules covalently,at least one of said two or more cationic components comprises at least one end amine group selected from the group consisting of —N(CH2)NH2, —N(CH2)2NH2, —N(CH2)3NH2, —N(CH2)N+H3, —N(CH2)2N+H3, —N(CH2)3N+H3 and a combination thereof, said at least one biodegradable bond is in the backbone of said biodegradable polymer, in at least one side chain of said at least one side chain of said biodegradable polymer, or in both said backbone and at least one side chain of said biodegradable polymer,said at least one biodegradable bond comprises a peptide bond, an ester bond, a reducible disulfide bond or a combination thereof, andsaid biomolecules comprise an amino acid, a lysine (Lys), a modified Lys, a glutamic acid (Glu), a modified Glu, an aspartic acid (Asp), a modified Asp, an arginine (Arg), a modified Arg, a linear polyLys, a branched polyLys, a linear polyGlu, a branched polyGlu, a linear polyArg, a branched polyArg or a combination thereof. 28. (canceled) 29. The bioactive composition of claim 27, wherein said at least one bioactive agent comprises an RNA, an mRNA, an RNAi, an siRNA, a microRNA, an oligonucleotide, a DNA, an oligodeoxynucleotide, a protein, a peptide, an antibody, a fragment of an antibody, a chemical compound, a chemotherapy drug, a small molecule drug, or a combination thereof. 30. The bioactive composition of claim 27, wherein said at least one bioactive agent comprises an antigen. 31. The bioactive composition of claim 27, wherein the said at least one bioactive agent comprises a DNA or an mRNA encoding at least one antigen, or a combination of the DNA and the mRNA encoding at least one antigen. 32. The bioactive composition of claim 27, wherein said at least one bioactive agent comprises a first oligodeoxynucleotide (ODN) attached to said biodegradable polymer through a non-covalent linkage. 33. The bioactive composition of claim 27, wherein said at least one bioactive agent further comprises an inhibitor or an activator of a bioprocess. 34. The bioactive composition of claim 27, wherein said biodegradable polymer and said at least one bioactive agent form nanoparticles in a range of from 1 nm to 1000 nm and said nanoparticles are soluble or dispersible in an aqueous solution. 35. The bioactive composition of claim 27 further comprising a polymer selected from the group consisting of a linear polymer, a branched polymer, a block copolymer, a graft copolymer, a dendrimer and a combination thereof, and wherein said biodegradable polymer and said polymer are the same or are different. 36. The bioactive composition of claim 35 further comprising a second oligodeoxynucleotide (ODN) attached to said biodegradable polymer through a covalent linkage, attached to said polymer through a covalent linkage, or attached to both through covalent linkages. 37. The bioactive composition of claim 35, wherein said polymer comprises a cationic polymer. 38. (canceled) 39. The bioactive composition of claim 27, wherein said bioactive composition comprises at least two bioactive agents, wherein a first of said at least two bioactive agents comprises a first RNA, mRNA, RNAi, siRNA, microRNA, oligonucleotide, DNA, oligodeoxynucleotide, chemical compound, chemotherapy drug, small molecule drug, a protein, a peptide, an antibody, a fragment of an antibody or a combination thereof; and a second of said at least two bioactive agents comprises a second RNA, mRNA, RNAi, siRNA, microRNA, oligonucleotide, DNA, oligodeoxynucleotide, chemical compound, chemotherapy drug, small molecule drug, protein, peptide, antibody, a fragment of an antibody or a combination thereof. 40. (canceled) 41. The bioactive composition of claim 27 further comprising a carrier, and said bioactive composition comprising a carrier comprises a pharmaceutical composition for treating a disease of a subject in need thereof. 42. (canceled) 43. The bioactive composition of claim 27 further comprising a targeting agent for targeting said bioactive composition to at least one target, wherein said targeting agent comprises a physical targeting agent, a chemical targeting agent, a biological target agent or a combination thereof. 44. (canceled) 45. The bioactive composition of claim 43, wherein said at least one target comprises a biosystem selected from the group consisting of cells in vitro, cells in vivo, nuclei of cells, cytoplasm of cells, extracellular matrix, tissues, body fluid of a subject, blood of the subject, an organ of the subject, a tumor of the subject, one or more cells selected from the group consisting of T cells, B cells, NK (natural killer) cells, cancer cells, tumor cells, antigen presenting cells (APC), dendritic cells (DC), neutrophils, macrophages, lymphocytes, monocytes and a combination thereof and a combination thereof. 46.-48. (canceled) 49. A method for treating a disease of a subject in need thereof, said method comprising the step of: introducing the bioactive composition of claim 27 to the subject, wherein said bioactive composition is introduced to the subject intravenously (IV), intramuscularly (IM), subcutaneously (SC), intradermally (ID), orally, through inhalation, nasally, ocularly or a combination thereof. 50. (canceled) 51. The method of claim 49 further comprising the step of: subsequently, introducing a second bioactive agent to the subject after the bioactive composition is introduced. 52. The method of claim 51, wherein said second bioactive agent comprises a second RNA, a second mRNA, a second RNAi, a second siRNA, a second microRNA, a second oligonucleotide, a second DNA, a second oligodeoxynucleotide, a second protein, a second peptide, a second antibody, a second fragment of an antibody, a second chemical compound, a second small molecule drug, or a combination thereof, and wherein said bioactive agent and said second bioactive agent are the same or different. 53. The method of claim 51, wherein said bioactive agent comprises an oligodeoxynucleotide (ODN) and said second bioactive agent comprises said RNA, mRNA, RNAi, siRNA, microRNA, oligonucleotide, DNA, oligodeoxynucleotide, protein, peptide, antibody, fragment of the antibody, chemical compound, small molecule drug, or a combination thereof. 54. The method of claim 51, wherein said bioactive agent comprises one or more chemotherapy drugs selected from the group consisting of a taxane, gemcitabine, carboplatin, cisplatin and a combination thereof, and said second bioactive agent comprises an oligodeoxynucleotide (ODN), a second chemotherapy drug, anti-PD1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies, anti-LAG3 antibodies, anti-TIM-3 antibodies, anti-CD19 antibodies, anti-CD20 antibodies, or a combination thereof. 55. The method of claim 54, wherein said bioactive composition or said second bioactive agent each is independently introduced to the subject intravenously (IV), intramuscularly (IM), subcutaneously (SC), intradermally (ID), orally, through inhalation, nasally, ocularly, or a combination thereof. 56-64. (canceled) 65. The bioactive composition of claim 27, wherein said biomolecules consist of lysine or polylysine. 66. The bioactive composition of claim 27, wherein said biodegradable polymer comprises a molecular weight of from 1,000 Da to about 1,500,000 Da and wherein each of said two or more cationic components has a molecular weight (MW) of from about 40 Da to about 5,000 Da. 67. The bioactive composition of claim 27, wherein each of said two or more cationic components independently comprises a linear polymer, a branched polymer, a hyperbranched polymer, a graft polymer, a block polymer, a dendrimer, or a combination thereof. 68. The bioactive composition of claim 27, wherein at least one of said two or more cationic components comprises lysine, polylysine, alkyleneimine, polymerized alkyleneimine, ethyleneimine, polymerized ethyleneimine (PEI), propyleneimine, polymerized propyleneimine (PPI), polymerized amidoamine (PAMAM), tris(2-aminoethyl)amine (TREN), polymerized tris(2-aminoethyl)amine, polyalkylamine, polyallylamine or a combination thereof. 69. The bioactive composition of claim 27, wherein said biodegradable polymer comprises one or more polymer segments, each having a formula: or a combination thereof, wherein, n and n′ each is an integer ≥0;x and x′ each is an integer ≥1;A is a biomolecule;B is selected from the group consisting of A, a linear polymer component comprising A, a branched polymer component comprising A, a dendrimer component comprising A and a combination thereof,wherein each of said one or more polymer segments comprises at least one of said at least one biodegradable bond; andP comprises a cationic component, P1, P2, P3 through Pi comprise said two or more cationic components, and wherein said two or more P1 through Pi are the same or are different. 70. The bioactive composition of claim 27, wherein said biodegradable polymer further comprises a polymer core comprising 2 or more branching reactive sites, and two or more polymer segments each of which is attached to said polymer core at one of said two or more branching reactive sites, and wherein said polymer core comprises a linear polymer, a branched polymer, a dendrimer, or a combination thereof, wherein said polymer core has a molecular weight of from 40 Da to 5,000 Da. 71. The bioactive composition of claim 70, wherein said polymer core comprises lysine, polylysine, polyaspartic acid, polyglutamic acid, polymerized alkyleneimine, alkyldiamine, ethylenediamine, polymerized ethyleneimine (PEI), propyleneimine, propylenediamine, polymerized propyleneimine (PPI), polymerized amidoamine (PAMAM), tris(2-aminoethyl)amine (TREN), polymerized tris(2-aminoethyl)amine, polyalkylamine, polyallylamine, polyol or a combination thereof. 72. The bioactive composition of claim 70, wherein said biodegradable polymer comprises a formula: or a combination thereof, wherein, n and n′ each is an integer ≥0;x and x′ each is an integer ≥1;A is a biomolecule;P comprises a cationic component, P1, P2, P3 through Pi comprise said two or more cationic components, and wherein said two or more P1 through Pi are the same or are different;D is said polymer core; andm and m′ each is an integer ≥0 and m+m′≥2. 73. The bioactive composition of claim 27, wherein said biodegradable polymer further comprises at least one hydrocarbon chain of from 3 to 30 carbon atoms (C3-C30), wherein said at least one hydrocarbon chain is covalently attached to said biodegradable polymer, said at least one hydrocarbon chain is attached to one of said biomolecules, one of said two or more cationic components, or a combination thereof, and said at least one hydrocarbon chain is a reacted unsaturated fatty acid, a saturated fatty acid, an epoxide derivative of said unsaturated fatty acid, an epoxide derivative of said saturated fatty acid or a combination thereof. 74. The bioactive composition of claim 73, wherein said at least one hydrocarbon chain comprises a reacted propionic acid, butyric acid, valeric acid, caproic acid, enanthic acid, caprylic acid, pelargonic acid, capric acid, undecylic acid, lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, nonadecylic acid, arachidic acid, heneicosylic acid, behenic acid, tricosylic acid, lignoceric acid, pentacosylic acid, cerotic acid, heptacosylic acid, montanic acid, nonacosylic acid, melissic acid, henatriacontylic acid, lacceroic acid, psyllic acid, geddic acid, ceroplastic acid, hexatriacontylic acid, heptatriacontanoic acid, octatriacontanoic acid, α-linolenic acid, stearidonic acid, eicosapentaenoic acid, docosahexaenoic acid, linoleic acid, linolelaidic acid, γ-linolenic acid, dihomo-γ-linolenic acid, arachidonic acid, docosatetraenoic acid, palmitoleic acid, vaccenic acid, paullinic acid, oleic acid, elaidic acid, gondoic acid, erucic acid, nervonic acid, mead acid, an isomer derivative thereof, an epoxide derivative thereof or a combination thereof. 75. The bioactive composition of claim 74, wherein said biomolecules consist of lysine or polylysine and said two or more cationic components comprise ethyleneimine, polymerized ethyleneimine (PEI), propyleneimine, polymerized propyleneimine (PPI), polymerized amidoamine (PAMAM) or a combination thereof.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.